MedTrace Logo

Dose Effect of Limicol on (LDL)-Cholesterol Levels

NCT01354340 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2012-04-19

No results posted yet for this study

Summary

The principal objective of this study is to investigate the dose-effect of the Limicol food supplement on LDL-cholesterol level in moderate hypercholesterolaemia subjects.

Conditions

  • Hypercholesterolaemia

Interventions

DIETARY_SUPPLEMENT

Limicol

3 tablets (Limicol) + 3 tablets (Placebo) / day during 1 month and follow-up 1 month without treatment

DIETARY_SUPPLEMENT

Limicol

6 tablets (Limicol) / day during 1 month and follow-up 1 month without treatment

OTHER

Placebo

6 tablets (Placebo) / day during 1 month and follow-up 1 month without treatment

Sponsors & Collaborators

  • BioFortis

    collaborator OTHER

  • Lescuyer Laboratory

    lead INDUSTRY

Principal Investigators

  • Sebastien Peltier, PhD · Lescuyer Laboratory

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2011-12-31
Completion
2012-01-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01354340 on ClinicalTrials.gov